We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Factor Xa-Based Antithrombin Assay Evaluated

By LabMedica International staff writers
Posted on 15 Nov 2011
A recently introduced antithrombin assay based on Factor Xa (FXa) has been evaluated on four different analyzers. More...


The INNOVANCE Antithrombin test is a new FXa-based chromogenic assay for automated quantification of functionally active anti-thrombin (AT) on coagulation analyzers.

Scientists working at Siemens Healthcare Diagnostic Products GmbH (Marburg, Germany) collaborated with investigators from the UK, Italy and another institution in Germany. They used clinical surplus plasma samples from 225 patients and 151 apparently healthy individuals from four different study sites to assay antithrombin.

The Siemens' INNOVANCE Antithrombin assay demonstrated on all analyzers repeatability coefficients of variation (CVs) ≤ 3.2% and within-device and between-run CVs ≤ 6.9%. The reference intervals of all analyzers are comparable with 2.5th percentiles between 80% and 85% of normal. The Siemens' INNOVANCE Antithrombin and the Factor IIa-based BerichromAT III (A) methods demonstrated good concordance with very high correlation coefficients.

The INNOVANCE Antithrombin method exhibited an excellent comparability with the STA Antithrombin III assay (Diagnostica Stago; Asnières sur Seine, France) and an acceptable comparability with the Coamatic LR Antithrombin assay (Instrumentation Laboratory, Bedford, MA, USA). The 31 patients with congenital deficiency were identified with all assays except for the patients carrying the P41L heparin-binding site mutation, which was only identified with the INNOVANCE Antithrombin and the STA Antithrombin III methods.

The authors concluded that this multicenter study demonstrates that the INNOVANCE antithrombin assay is precise and reliable to aid in the diagnosis of antithrombin deficiency. The advantages of this assay compared to the other methods were the higher sensitivity for heparin-binding site mutations, the liquid ready-to-use reagents, and the absence of interference by direct thrombin inhibitors. The study was published in October 2011, in the journal International Journal of Laboratory Hematology.

Related Links:
Siemens Healthcare Diagnostic Products
Diagnostica Stago
Instrumentation Laboratory


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.